1. Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

2. Glioblastoma: The Current State of Affairs

3. No Improvement With Temozolomide Dose Intensification or Treatment Prolongation

4. Treatment at Recurrence

5. Glioblastoma: Improving Outcomes

6. No Survival Benefit of Adding Bevacizumab to Standard of Care, Despite Improved PFS

7. Immunotherapy: No Established Improvement of Outcome in Glioblastoma

8. Promise of Personalized Treatment Strategies Has Not Yet Delivered for Glioblastoma and Other Gliomas

9. EGFR and Glioblastoma: Still a Relevant Target?

10. Trials of EGFR Inhibition in Recurrent Glioblastoma Invariably Failed

11. Why Did We Fail, Despite the Prominent Role of EGFR Signalling in Glioblastoma?

12. BRAF Mutations in Glioma: An Actionable Target

13. Ongoing Inhibitor Studies With EGFR Inhibitors

14. Nanocell, EGFR, and Doxorubicin: EnGeneIC Delivery Vehicle (EDV)

15. Current Approaches to Targeted Therapies: Ligand‑Compound Constructs

16. Antibody-Drug Conjugates: A Novel and Clinically Successful Approach

17. Antibody-Drug Conjugates: Proof of Concept and MOA

18. Depatux-M (ABT-414): ADC of ABT-806 With MMAF Attached

19. Phase 1 M12-356: Depatux-M in EGFR-Amplified GBM

20. Depatux-M: Toxicity Profile

21. Depatux-M: Toxicity Profile: Response and Duration of Study in Phase 1 Expansion Cohorts on EGFR-Amplified Recurrent GBM

22. Depatux-M: Clinical Development Program: INTELLANCE1 and INTELLANCE2 Pivotal Studies

23. INTELLANCE 2 Phase 2 Trial Design M14-483/EORTC-1410-BTG

24. Long-Term Follow-Up: Treatment and Time Since TMZ

25. Long-Term Follow-Up: Treatment and Methylation Status

26. Depatux-M: Current Status

27. Rindopepimut: EGFRvIII Vaccination

28. Adoptive T-Cell Therapy With CAR-Redirected T Lymphocytes

29. CAR-T Cells: A Treatment Alternative in Glioma?

30. Conclusion: Ongoing Approaches Targeting EGFR

31. Abbreviations

32. Abbreviations (cont)